CMPS — COMPASS Pathways Share News
0.000.00%
Last trade - 00:00Compass Pathways' depression drug meets main goal in late-stage trial (updated)
Compass Pathways' depression drug succeeds late-stage trial
Brief: Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial
Compass Pathways PLC reports results for the quarter ended March 31 - Earnings Summary
Compass Pathways PLC expected to post a loss of 47 cents a share - Earnings Preview
Brief: Compass Pathways Establishes Strategic Collaboration With Healthport
Brief: Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin
U.S. STOCKS ON THE MOVE-Dow, Nike, Coty
U.S. STOCKS ON THE MOVE-Caterpillar, Netflix, Bank of America
Jefferies says J&J's depression drug sales bode well for psychedelics
Brief: Compass Pathways Announces Completion Of Recruitment For The Phase 3 COMP005 Trial Of COMP360 Psilocybin For Treatment-Resistant Depression
Compass Pathways PLC reports results for the quarter ended December 31 - Earnings Summary
Brief: COMPASS Pathways Q4 EPS USD -0.63
Compass Pathways PLC expected to post a loss of 62 cents a share - Earnings Preview
Brief: Compass Pathways To Announce Q4 And FY Results On Feb 27, 2025
Brief: Compass Pathways Announces Pricing Of Underwritten Offering
U.S. STOCKS ON THE MOVE-FuelCell Energy, consumer goods stocks, Rocket Companies
Psychedelic drug developers rise after RFK Jr picked for top US health agency role
U.S. STOCKS ON THE MOVE-OneStream, FuelCell Energy, Alibaba